← Back to Search

Anti-tumor antibiotic, Anti-metabolites

CLAG-M for Lymphoblastic Lymphoma

Phase 2
Waitlist Available
Led By Karen Seiter, MD
Research Sponsored by New York Medical College
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Relapsed or refractory acute lymphoblastic leukemia
Burkitts leukemia/lymphoma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.

Eligible Conditions
  • Lymphoblastic Lymphoma
  • Burkitt Lymphoma
  • Leukemia
  • Acute Lymphoblastic Leukemia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Complete remission percentage
Secondary outcome measures
Survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: CLAG-MExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

New York Medical CollegeLead Sponsor
69 Previous Clinical Trials
5,961 Total Patients Enrolled
Karen Seiter, MDPrincipal InvestigatorNew York Medical College
1 Previous Clinical Trials
100 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~4 spots leftby Mar 2025